S.Korea’s SK bioscience to invest $132 million to boost vaccine production
The word “COVID-19” is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS FILE PHOTO
SEOUL — South Korea’s SK bioscience said on Monday it plans to expand vaccine production by investing about 150 billion won ($132 million) by 2024 to add production capacity, as well as equipping its plant to make newer mRNA and viral vector vaccines.
The vaccine maker said in a statement it has signed an agreement with the government of North Gyeongsang Province and the city of Andong, about 190 km (118 miles) southeast of Seoul, to expand its plant there and buy new land.
SK bioscience said it plans to add some 99,130 square meters of additional production space in the area.
Its Andong plant produces COVID-19 vaccines developed by AstraZeneca Plc and Novavax Inc.
The company said last week the facility had received European Union Good Manufacturing Practices (GMP) certification, enabling SK to export vaccines to Europe.
($1 = 1,138.5300 won)
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
